ScoreComparison
Why is 4D Molecular Therapeutics, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -74.33% and Operating profit at -230.67% over the last 5 years
2
Flat results in Sep 25
- ROCE(HY) Lowest at -45.38%
- OPERATING PROFIT(Q) Lowest at USD -59.18 MM
- PRE-TAX PROFIT(Q) Lowest at USD -56.86 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 135.46%, its profits have fallen by -72.5%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is 4D Molecular Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
4D Molecular Therapeutics, Inc.
135.46%
-0.61
96.94%
S&P 500
16.12%
0.84
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-74.33%
EBIT Growth (5y)
-230.67%
EBIT to Interest (avg)
-108.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.67
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.17
EV to EBIT
-0.58
EV to EBITDA
-0.60
EV to Capital Employed
1.91
EV to Sales
133.18
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-330.93%
ROE (Latest)
-56.70%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
NET SALES(HY)
At USD 0.1 MM has Grown at 1,212.5%
NET PROFIT(HY)
Higher at USD -111.51 MM
RAW MATERIAL COST(Y)
Fallen by -96.25% (YoY
-12What is not working for the Company
ROCE(HY)
Lowest at -45.38%
OPERATING PROFIT(Q)
Lowest at USD -59.18 MM
PRE-TAX PROFIT(Q)
Lowest at USD -56.86 MM
NET PROFIT(Q)
Lowest at USD -56.86 MM
Here's what is working for 4D Molecular Therapeutics, Inc.
Net Sales
At USD 0.1 MM has Grown at 1,212.5%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Raw Material Cost
Fallen by -96.25% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 2 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for 4D Molecular Therapeutics, Inc.
Operating Profit
Lowest at USD -59.18 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Pre-Tax Profit
Lowest at USD -56.86 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -56.86 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
